PTSD, Depression, Prescription Drug Use, and Health Care Utilization of Chinese Workers Affected by the WTC Attacks

2006 ◽  
Vol 8 (3) ◽  
pp. 203-210 ◽  
Author(s):  
Heike Thiel de Bocanegra ◽  
Sophia Moskalenko ◽  
Elizabeth J. Kramer
2009 ◽  
Vol 11 (1) ◽  
Author(s):  
Kerstin Bingefors

<strong><span style="font-family: TimesNewRomanPS-BoldMT;"><font face="TimesNewRomanPS-BoldMT"><p align="left"> </p></font></span><p align="left"><span style="font-size: x-small; font-family: TimesNewRomanPS-BoldMT;"><span style="font-size: x-small; font-family: TimesNewRomanPS-BoldMT;">ABSTRACT</span></span></p></strong><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><p align="left">Much of our knowledge of drugs originates from clinical trials of drug efficacy performed on stringently</p><p align="left">selected patient groups, often without multiple concurrent diseases. However, the effectiveness of treatment</p><p align="left">under conditions of use in ordinary clinical practice may be very different to conditions in the</p><p align="left">randomised clinical trial. Use of large computerised data bases and record linkage has thus become</p><p align="left">increasingly common in pharmacoepidemiologic research. The greatest advantages of using routinely</p><p align="left">collected data are the minimisation of study costs and time required to complete a study, considerations</p><p align="left">that are particularly relevant for longitudinal studies. The advantages of using data bases also include the</p><p align="left">possibility of obtaining large sample sizes and to retrospectively study long-term outcomes. The risk for</p><p align="left">recall bias, a significant problem in interviews and questionnaires, is also reduced. However, computerised</p><p align="left">data bases also have some potentially serious disadvantages, primarily in the areas of data validity</p><p align="left">and data availability. The Tierp study, including individually based data bases of prescription drug use,</p><p align="left">will be used here as an example of research. In this paper an example of a comprehensive data base study</p><p align="left">concerning health care and drug utilisation in depressed patients is presented. Methodological considerations</p><p align="left">in data base research are discussed in relation to experiences from the antidepressant study. A well</p><p align="left">planned and research oriented computerised data base on prescription drugs represents an important tool</p><p>in the study of the outcome of drug treatment in real world clinical practice.</p></span></span>


Dermatitis ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Zarqa Ali ◽  
Charlotte Suppli Ulrik ◽  
Alexander Egeberg ◽  
Jacob Pontoppidan Thyssen ◽  
Simon Francis Thomsen

2015 ◽  
Vol 36 (4) ◽  
pp. 407-412 ◽  
Author(s):  
Susan L. Calcaterra ◽  
Angela Keniston ◽  
Joshua Blum ◽  
Tessa Crume ◽  
Ingrid A. Binswanger

2021 ◽  
Vol 135 ◽  
pp. 230-236
Author(s):  
Casey Crump ◽  
Kenneth S. Kendler ◽  
Jan Sundquist ◽  
Alexis C. Edwards ◽  
Kristina Sundquist

2019 ◽  
Vol 65 (5) ◽  
pp. 338-346 ◽  
Author(s):  
Julie-Anne Tanner ◽  
Jennifer Hensel ◽  
Paige E. Davies ◽  
Lisa C. Brown ◽  
Bryan M. Dechairo ◽  
...  

Objectives To characterize the health-care utilization and economic burden associated with depression in Manitoba, Canada. Methods Patient-level data were retrieved from the Manitoba Centre for Health Policy administrative, clinical, and laboratory databases for the study period of January 1, 1996, through December 31, 2016. Patients were assigned to the depression cohort based on diagnoses recorded in hospitalizations and outpatient physician claims, as well as antidepressant prescription drug claims. A comparison cohort of nondepressed subjects, matched with replacement for age, gender, place of residence (urban vs. rural), and index date, was created. Demographics, comorbidities, intentional self-harm, mortality, health-care utilization, prescription drug utilization, and costs of health-care utilization and social services were compared between depressed patients and matched nondepressed patients, and incidence rate ratios and hazard ratios were reported. Results There were 190,065 patients in the depression cohort and 378,177 patients in the nondepression cohort. Comorbidities were 43% more prevalent among depressed patients. Intentional self-harm, all-cause mortality, and suicide mortality were higher among patients with depression than the nondepression cohort. Health-care utilization—including hospitalizations, physician visits, physician-provided psychotherapy, and prescription drugs—was higher in the depression than the nondepression cohort. Mean health-care utilization costs were 3.5 times higher among depressed patients than nondepressed patients ($10,064 and $2,832, respectively). Similarly, mean social services costs were 3 times higher ($1,522 and $510, respectively). Overall, depression adds a total average cost of $8,244 ( SD = $40,542) per person per year. Conclusions Depression contributes significantly to health burden and per patient costs in Manitoba, Canada. Extrapolation of the results to the entire Canadian health-care system projects an excess of $12 billion annually in health system spending.


2017 ◽  
Vol 189 (19) ◽  
pp. E690-E696 ◽  
Author(s):  
Michael R. Law ◽  
Lucy Cheng ◽  
Heather Worthington ◽  
Muhammad Mamdani ◽  
Kimberlyn M. McGrail ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document